+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer



ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer



Seminars in Oncology 29(1 Suppl 4): 37-46



The epidermal growth factor receptor is overexpressed in a majority of non-small cell lung cancers and has been associated with a poor prognosis. Preclinical studies have shown that ZD1839, an oral anilinoquinazoline, targets the epidermal growth factor receptor-associated tyrosine kinase, reversibly inhibiting critical downstream signaling and resulting in cancer cell growth arrest. Potent antitumor effects have been observed in human lung tumor xenograft models. Preclinical studies have shown additive to synergistic effects when ZD1839 is combined with radiation or chemotherapy in colon, head and neck, and non-small cell lung cancers. Phase I clinical trials have shown modest dose-related toxicity, and antitumor activity has been reported in a variety of malignancies including lung cancer. Future studies will certainly combine ZD1839 with chemotherapy or radiation. ZD1839 also may be effective as a chemoprevention agent because premalignant lesions often overexpress epidermal growth factor receptor.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047991598

Download citation: RISBibTeXText

PMID: 11894012

DOI: 10.1053/sonc.2002.31521


Related references

Erlotinib (OSI-774, Tarceva), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer. Clinical Lung Cancer 4(6): 336-338, 2003

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology 20(18): 3815-3825, 2002

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clinical Cancer Research 9(6): 2040-2048, 2003

Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549. Ai Zheng 26(12): 1299-1303, 2007

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Molecular Cancer Therapeutics 3(8): 977-983, 2004

Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?. Translational Lung Cancer Research 5(1): 98, 2016

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Lung Cancer 128: 6, 2019

Synergistic antitumor activity of ZD1839 , an epidermal growth factor receptor tyrosine kinase inhibitor , in combination with vinorelbine in human lung cancer xenografts. Proceedings of the American Association for Cancer Research Annual Meeting 44: 740-741, 2003

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical Cancer Research 9(4): 1566-1572, 2003

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer 40(3): 301-307, 2003

Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. International Journal of Oncology 25(1): 203-210, 2004

Inhibition of p21-activated kinase 1, directional cell motility and invasion of growth-factor-activated human cancer cells by the selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Proceedings of the American Association for Cancer Research Annual Meeting 43: 157-158, 2002

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. British Journal of Cancer 92(1): 125-130, 2004

49P * Synergistic Effect Of Histone Deacetylase Inhibitor In Combination With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor In Egfr-Tki Resistant Non-Small Cell Lung Cancer Cell Lines. Annals of Oncology 26(Suppl 1): i13-i14, 2015

Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and the anti-androgen bicalutamide. EJC Suppl.s 1(5): S265, 2003